BioNote바이오노트
377740 · KOSPI · ₩377740 · 바이오노트
- Market cap
- ₩464B
- Enterprise value
- ₩397B
- P/E
- —
- P/B
- 0.3×
- Dividend yield
- 5.0%
- ROE
- −8.1%
- Net margin
- −99.4%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−27.2% from the high
₩4,050Today: ₩4,455 – ₩4,620₩6,260
Returns
- 1W−0.1%
- 1M−1.9%
- 3M+3.4%
- 6M−11.9%
- YTD−16.7%
- 1Y−17.5%
- Volume today
- 40,054
- 0.8× the 20-day average
- Traded today
- ₩183M
- Listed shares
- 101,886,048
- EPS (12 months)
- −₩1,234
- Earnings yield −27.1%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 40 of 100 (50 is a normal day for this stock).
- SentimentMixedNews: Only routine filings about a shareholders' meeting and record date. Community: 0 bullish, 0 bearish posts this week.
- MomentumFlat-2.5% over the last month; the price is below its 20-day average.
- News impactLow3 news items and filings in two weeks; 0 rated high impact, 0 medium.
Signals describe activity, not recommendations. Not financial advice.
BioNote stock overview
BioNote (바이오노트, KRX: 377740) is listed on KOSPI, in the Biotech & Pharma sector. The company, founded in 2003, develops, manufactures and distributes veterinary diagnostic test products and bio-content materials based on its proprietary recombinant antigen and antibody technology. Its shares closed at ₩4,555 on Oct 27, 2026, down 0.87% on the day, giving it a market value of ₩464B.
Key facts
- Market cap
- ₩464B
- Sector
- Biotech & Pharma
- Latest price change
- −0.87%
- As of
- Oct 27, 2026
- Main business
- The company, founded in 2003, develops, manufactures and distributes veterinary diagnostic test products and bio-content materials based on its proprietary recombinant antigen and antibody technology.
Quick answers about BioNote
- What does BioNote do?
- The company, founded in 2003, develops, manufactures and distributes veterinary diagnostic test products and bio-content materials based on its proprietary recombinant antigen and antibody technology. Its main offerings include BIONOTE Rapid rapid immunochemical tests, Vcheck F fluorescence immunodiagnostic devices and reagents, BIONOTE ELISA tests, and intermediate products and raw materials such as antigens, antibodies and enzymes. Its main customers are overseas distributors and affiliated companies, and it sells in multiple countries, including government tenders abroad.
- What is the market cap of BioNote?
- The market capitalisation of BioNote was ₩464B at the close on Oct 27, 2026.
- Who are the largest shareholders of BioNote?
- According to the latest official filings, the largest reported holders are Jo Yeong-sik (73.86%, as of Apr 21, 2026); Cho Hye-im (16.39%, as of Feb 5, 2025); National Pension Service (0.81%, as of Dec 31, 2025).
- When is the next earnings report from BioNote?
- Korean companies rarely announce results dates in advance. Based on when BioNote filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
- Does the National Pension Service own BioNote?
- Yes. The National Pension Service held 0.81% of BioNote shares as of Dec 31, 2025.
Company profile
The company, founded in 2003, develops, manufactures and distributes veterinary diagnostic test products and bio-content materials based on its proprietary recombinant antigen and antibody technology. Its main offerings include BIONOTE Rapid rapid immunochemical tests, Vcheck F fluorescence immunodiagnostic devices and reagents, BIONOTE ELISA tests, and intermediate products and raw materials such as antigens, antibodies and enzymes. Its main customers are overseas distributors and affiliated companies, and it sells in multiple countries, including government tenders abroad.
Written by AI from the company's latest annual report.
- Korean name
- 바이오노트
- Sector
- Biotech & Pharma
- Themes
- Medical devices
- CEO
- 조병기
- Founded
- Mar 2003
- Listed
- Dec 2022
- Listed shares
- 101,886,048
- Fiscal year ends
- Month 12
- Website
- www.bionote.co.kr
Similar companies
- Samsung Biologics207940 · ₩64T₩1,374,000−5.37%
- Celltrion068270 · ₩44T₩188,600−0.74%
- Alteogen196170 · ₩15T₩218,5000.00%
- Yuhan000100 · ₩5.9T₩80,000−2.08%
- SK biopharmaceuticals326030 · ₩5.9T₩74,900−1.19%
- HLB028300 · ₩5.3T₩39,900+1.66%
- Hanmi Pharm128940 · ₩4.5T₩350,500−0.57%
- SAM Chun Dang Pharm000250 · ₩4.4T₩187,600−0.69%
Recent filings
See all- Determination of Shareholder Register Closure Period or Record DateOct 26, 2026
- Shareholders' meeting calledOct 26, 2026
- Corporate value-up planOct 22, 2026
- Half-year report (Jun 2026)Aug 13, 2026
- Preliminary earnings (consolidated)Aug 6, 2026
Titles in Korean until English translations are added.
Also known as: BioNote / 바이오노트 / 377740 / KRX:377740
Source: KRX statistical information